$1.11
0.45% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US75120L1008
Symbol
RLYB

Rallybio Corp Stock price

$1.11
-0.14 10.89% 1M
-0.49 30.50% 6M
-1.29 53.77% YTD
-2.42 68.61% 1Y
-12.84 92.07% 3Y
-13.00 92.16% 5Y
-13.00 92.16% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.01 0.45%
ISIN
US75120L1008
Symbol
RLYB
Sector
Industry

Key metrics

Market capitalization $46.05m
Enterprise Value $-42.28m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.78
EV/Sales (TTM) EV/Sales -140.93
P/S ratio (TTM) P/S ratio 153.50
P/B ratio (TTM) P/B ratio 0.58
Revenue (TTM) Revenue $300.00k
EBIT (operating result TTM) EBIT $-77.30m
Free Cash Flow (TTM) Free Cash Flow $-54.00m
Cash position $88.61m
EPS (TTM) EPS $-1.79
P/E forward negative
P/S forward 153.70
EV/Sales forward negative
Short interest 1.87%
Show more

Is Rallybio Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Rallybio Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Rallybio Corp forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Rallybio Corp forecast:

Buy
83%
Hold
17%

Financial data from Rallybio Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.30 0.30
-
100%
- Direct Costs 0.14 0.14
13% 13%
47%
0.16 0.16
200% 200%
53%
- Selling and Administrative Expenses 22 22
17% 17%
7,453%
- Research and Development Expense 55 55
17% 17%
18,317%
-77 -77
4% 4%
-25,720%
- Depreciation and Amortization 0.14 0.14
13% 13%
47%
EBIT (Operating Income) EBIT -77 -77
4% 4%
-25,766%
Net Profit -74 -74
5% 5%
-24,627%

In millions USD.

Don't miss a Thing! We will send you all news about Rallybio Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rallybio Corp Stock News

Neutral
Business Wire
5 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune th...
Neutral
Business Wire
18 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that Fierce Life Sciences and Fierce Healthcare has named Rallybio an Innovation Honoree as part of the 2024 Fierce 50 list. The Fierce 50 showcases 50 individuals...
Neutral
Business Wire
30 days ago
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that data from the Phase 1 proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of maternal alloimmunizatio...
More Rallybio Corp News

Company Profile

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focuses in the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Head office United States
CEO Stephen Uden
Employees 43
Founded 2018
Website www.rallybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today